VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
“During this fall we expect to add about 15 new hospitals to our study. As active patient enrollment starts up in these centers we should see many more patients being enrolled every month,” stated CEL-SCI Chief Executive Officer Geert Kersten.
Help employers find you! Check out all the jobs and post your resume.
